Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: A study of the Eastern Cooperative Oncology Group (ECOG), E5995

Leukemia Research

Volumn 24, Issue 10, 2000, Pages 871-875

  Gordon, Michael S ^a   Young, Molly L ^a   Tallman, Martin S ^a   Cripe, Larry D ^a   Bennett, John M ^a   Paietta, Elisabeth ^a   Longo, Walter ^a   Gerad, Henry ^a   Mazza, Joseph ^a   Rowe, Jacob M ^a  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

2 Chlorodeoxyadenosine; Acute myeloid leukemia; Chemotherapy; Purine analog; Salvage therapy

Indexed keywords

CLADRIBINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INFECTION; MALE; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; STOMATITIS; SURVIVAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CLADRIBINE; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; RECURRENCE;

EID: 0033843386     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00043-6     Document Type: Article

References (23)

1. Biggs J.C., Horowitz M.M., Gale R.P., Ash R.C., Atkinson K., Helbig W. et al. Bone marrow transplantation may cure patients with acute leukemia never achieving remission with chemotherapy. Blood. 80:1992;1090.
2. Wiernik P. Acute Leukemias. DeVita V.J., Hellman S., Rosenberg S. Cancer - Principles and Practice of Oncology. third ed:1989;J.B. Lippincott Co, Philadelphia, PA.
3. Schwartz M.A., Lovett D.R., Redner A., Finn R.D., Graham M.C., Divgi C.R. et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J. Clin. Oncol. 11:1993;294.
4. Ohno R., Okada K., Masaoka T., Kuramoto A., Arima T., Yoshida Y. et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J. Clin. Oncol. 8:1990;1907.
5. Kantarjian H.M., Beran M., Ellis A., Zwelling L., O'Brien S., Cazenave L. et al. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 81:1993;1146.
6. Kawasaki H., Carrera C., Piro L., Saven A., Kipps T., Carson D. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood. 81:1993;597.
7. Huang M.C., Ashmun R.A., Avery T.L., Kuehl M., Blakley R.L. Effects of cytotoxicity of 2-chloro-2′-deoxyadenosine and 2-bromo-2′-deoxyadenosine on cell growth, clonogenicity, DNA synthesis, and cell cycle kinetics. Cancer Res. 46:1986;2362.
8. Avery T.L., Rehg J.E., Lumm W.C., Harwood F.C., Santana V.M., Blakley R.L. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromo-deoxyadenosine in drug combinations in mice. Cancer Res. 49:1989;4972.
9. Parker W.B., Bapat A.R., Shen J.X., Townsend A.J., Cheng Y.C. Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol. Pharmacol. 34:1988;485.
10. Parker W.B., Shaddix S.C., Chang C.H., White E.L., Rose L.M., Brockman R.W. et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. 51:1991;2386.
11. Griffin J., Koob R., Blakely R. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res. 49:1989;6923.
12. Carson D.A., Wasson D.B., Kaye J., Ullman B., MartinJr D.W., Robins R.K. et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs towards malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Am. Acad. Sci. USA. 77:1980;6865.
13. Parsons P.G., Hayward I.P. Human melanoma cells sensitive to deoxyadenosine and deoxyinosine. Biochem. Pharmacol. 35:1986;655.
14. Hutton J., von Hoff D. Cytotoxicity of 2-chlorodeoxyadenosine in a human tumor colony-forming assay. Cancer Drug Deliv. 3:1986;115.
15. Santana V.M., Mirro Jr J., Harwood F.C., Cherrie J., Schell M., Kalwinsky D. et al. A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J. Clin. Oncol. 9:1991;416.
16. Larson R., Mick R., Spielberger R., O'Brien S.M. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J. Clin. Oncol. 14:1996;188.
17. Vahdat L., Wong E., Wile M., Rosenblum M., Foley K., Warrell R.J. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood. 84:1994;3429.
18. Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield C.D. et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol. 8:1990;813.
19. Schiller G. Treatment of resistant acute myeloid leukemia. Blood Rev. 5:1991;220.
20. Santana V., Mirro J.J., Kearns C., Schell M., Crom W., Blakley R. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J. Clin. Oncol. 10:1992;364.
21. Kornblau S., Andreef M., Beran M., Escudier S., Kantarjian H., Koller C. et al. 2-CdA+Ara-C is ineffective therapy for relapsed or refractory AML in adults. Proc. Am. Soc. Clin. Oncol. 14:1995;1005a.
22. Juliusson G., Liliemark J. 2-chlorodeoxyadenosine (CDA) with and without cytosine arabinoside (ara-c) and idarubicin for acute myeloid and lymphoid leukemia - clinical and pharmacokinetic studies. Br. J. Haematol. 87:1994;48a.
23. Estey E., Thall P., Kantarjian H., Pierce S., Freireich E. Role of fludarabine containing regimens in newly diagnosed AML or MDS. Blood. 92:1998;952a.